GlaxoSmithKline must have been feeling generous: the pharma gave $25 million to the Harvard Stem Cell Institute for a five-year partnership "to develop new methods for screening drugs with stem cells," according to this news item from Technology Review. "The time appears ripe for investing, because scientists can now use new reprogramming techniques to develop stem cells from patients with specific diseases."
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.